Reddy B S, Rao C V, Rivenson A, Kelloff G
Division of Nutritional Carcinogenesis, American Health Foundation, Valhalla, NY 10595.
Carcinogenesis. 1993 Aug;14(8):1493-7. doi: 10.1093/carcin/14.8.1493.
Epidemiologic studies suggest that sustained use of aspirin may reduce the risk of development of and mortality due to colon cancer. Previous preclinical studies have shown that several non-steroidal anti-inflammatory drugs act as potential chemopreventive agents in experimentally induced colon cancer models. The present study was designed to investigate the chemopreventive effect of 40 and 80% maximum tolerated dose (MTD) levels of aspirin administered in the diet on azoxymethane (AOM)-induced colon carcinogenesis in male F344 rats. The MTD of aspirin as determined in male F344 rats was 500 p.p.m. Beginning at 5 weeks of age, all animals were randomly divided into various experimental groups (48 rats/group) and fed one of the semipurified diets containing 0, 200 p.p.m. (40% MTD), or 400 ppm (80% MTD) of aspirin. Two weeks later, all animals (36 rats/group) except the vehicle-treated groups (12 rats/group) were administered s.c. injections of AOM at a dose level of 15 mg/kg body wt, once weekly for 2 weeks. All animals were continued on their respective dietary regimen for additional 52 weeks and necropsied. Histopathologic evaluation of colon tumors was performed by routine procedures. Basal levels and ex vivo production of colonic mucosal and tumor prostaglandin E2 (PGE2) were measured in all groups. The results indicate that daily oral administration of 200 and 400 p.p.m. aspirin significantly inhibited the incidence (% animals with tumors) and multiplicity (tumors/animal) of invasive adenocarcinomas of the colon as well as the size of adenocarcinomas. Colonic mucosal and tumor PGE2 levels (basal and ex vivo production) were significantly reduced in animals administered 200 and 400 p.p.m. aspirin. The results of this study support the epidemiologic evidence that ingestion of aspirin inhibits colon carcinogenesis. Although the precise mechanisms of aspirin-induced colon tumor inhibition remain to be determined, it is likely that the effect may be mediated through the modulation of prostaglandin synthesis.
流行病学研究表明,持续使用阿司匹林可能会降低结肠癌的发病风险和死亡率。先前的临床前研究表明,几种非甾体抗炎药在实验诱导的结肠癌模型中可作为潜在的化学预防剂。本研究旨在调查饮食中给予40%和80%最大耐受剂量(MTD)水平的阿司匹林对雄性F344大鼠中由氧化偶氮甲烷(AOM)诱导的结肠癌发生的化学预防作用。在雄性F344大鼠中确定的阿司匹林MTD为500 ppm。从5周龄开始,将所有动物随机分为不同的实验组(每组48只大鼠),并喂食含有0、200 ppm(40% MTD)或400 ppm(80% MTD)阿司匹林的半纯化饮食之一。两周后,除溶剂处理组(每组12只大鼠)外,所有动物(每组36只大鼠)均皮下注射剂量为15 mg/kg体重的AOM,每周一次,共2周。所有动物继续其各自的饮食方案另外52周,然后进行尸检。通过常规程序对结肠肿瘤进行组织病理学评估。在所有组中测量结肠黏膜和肿瘤前列腺素E2(PGE2)的基础水平和体外产生量。结果表明,每日口服200和400 ppm的阿司匹林可显著抑制结肠浸润性腺癌的发生率(有肿瘤的动物百分比)和多发性(肿瘤/动物)以及腺癌的大小。给予200和400 ppm阿司匹林的动物中结肠黏膜和肿瘤PGE2水平(基础水平和体外产生量)显著降低。本研究结果支持了摄入阿司匹林可抑制结肠癌发生的流行病学证据。尽管阿司匹林诱导结肠肿瘤抑制的确切机制仍有待确定,但这种作用可能是通过调节前列腺素合成介导的。